ArticleAmerican journal of cancer research2025
Prognostic value of immunoinflammatory indicators and tumor markers for first-line chemotherapy in patients with non-small cell lung cancer.
Article in American journal of cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Immune-inflammatory-fibrinogen score as a novel prognostic biomarker in patients with gastric cancer undergoing radical gastrectomy: a multicenter study.World journal of surgical oncology · 2026Trial
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the prognostic significance of immunoinflammatory indicators and tumor markers in patients with non-small cell lung cancer (NSCLC) undergoing first-line chemotherapy.
methodsThis retrospective study included 306 NSCLC patients treated with first-line chemotherapy between January 2022 and January 2023. Clinical data, including demographic information, clinicopathological features, immunoinflammatory markers, and tumor markers, were collected. Survival was analyzed using Kaplan-Meier curves and compared with the log-rank test. Cox proportional hazards models were used to identify factors associated with overall survival (OS). Logistic regression was applied to predict 2-year mortality risk, and model performance was evaluated using receiver operating characteristic curves, area under the curve (AUC), calibration plots, and decision curve analysis.
resultsBy the end of follow-up, 183 patients had died (mortality rate: 59.80%). Univariate analysis showed that high neutrophil-to-lymphocyte ratio (NLR), high platelet-to-lymphocyte ratio (PLR), low lymphocyte-to-monocyte ratio (LMR), and elevated levels of CEA, CA125, and CYFRA 21-1 were significantly associated with worse prognosis (all P<0.001). Multivariate analysis identified high PLR (HR=1.94, P=0.041) and high CEA (HR=2.13, P=0.002) as independent risk factors, while high LMR (HR=0.52, P=0.043) was protective. A logistic model combining CEA, PLR, and LMR showed high predictive accuracy for 2-year mortality (AUC=0.926).
conclusionCombined assessment of immunoinflammatory and tumor markers improves prognostic accuracy in NSCLC patients receiving first-line chemotherapy and may guide individualized treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.